These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
255 related articles for article (PubMed ID: 32920974)
1. Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm. Castiglione M; Jiang YP; Mazzeo C; Lee S; Chen JS; Kaushansky K; Yin W; Lin RZ; Zheng H; Zhan H J Thromb Haemost; 2020 Dec; 18(12):3359-3370. PubMed ID: 32920974 [TBL] [Abstract][Full Text] [Related]
2. Decoding Endothelial MPL and JAK2V617F Mutation: Insight Into Cardiovascular Dysfunction in Myeloproliferative Neoplasms. Zhang H; Kafeiti N; Masarik K; Lee S; Yang X; Zheng H; Zhan H Arterioscler Thromb Vasc Biol; 2024 Sep; 44(9):1960-1974. PubMed ID: 38989576 [TBL] [Abstract][Full Text] [Related]
3. JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles. Hekimoğlu H; Toprak SF; Sözer S Turk J Haematol; 2022 Feb; 39(1):13-21. PubMed ID: 34981912 [TBL] [Abstract][Full Text] [Related]
4. JAK2V617F mutant endothelial cells promote neoplastic hematopoiesis in a mixed vascular microenvironment. Mazzeo C; Quan M; Wong H; Castiglione M; Kaushansky K; Zhan H Blood Cells Mol Dis; 2021 Sep; 90():102585. PubMed ID: 34139651 [TBL] [Abstract][Full Text] [Related]
5. The JAK2V617F-bearing vascular niche promotes clonal expansion in myeloproliferative neoplasms. Zhan H; Lin CHS; Segal Y; Kaushansky K Leukemia; 2018 Feb; 32(2):462-469. PubMed ID: 28744010 [TBL] [Abstract][Full Text] [Related]
6. Thrombosis in myeloproliferative neoplasms with JAK2V617F mutation. Sun T; Zhang L Clin Appl Thromb Hemost; 2013; 19(4):374-81. PubMed ID: 22826442 [TBL] [Abstract][Full Text] [Related]
7. A Murine Model With JAK2V617F Expression in Both Hematopoietic Cells and Vascular Endothelial Cells Recapitulates the Key Features of Human Myeloproliferative Neoplasm. Zhang H; Yeware A; Lee S; Zhan H Front Oncol; 2021; 11():753465. PubMed ID: 34765558 [TBL] [Abstract][Full Text] [Related]
9. [Myeloproliferative neoplasms and vascular diseases]. Ikeda K Rinsho Ketsueki; 2022; 63(9):1107-1114. PubMed ID: 36198536 [TBL] [Abstract][Full Text] [Related]
10. JAK2V617F-positive endothelial cells contribute to clotting abnormalities in myeloproliferative neoplasms. Etheridge SL; Roh ME; Cosgrove ME; Sangkhae V; Fox NE; Chen J; López JA; Kaushansky K; Hitchcock IS Proc Natl Acad Sci U S A; 2014 Feb; 111(6):2295-300. PubMed ID: 24469804 [TBL] [Abstract][Full Text] [Related]
11. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study. Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441 [TBL] [Abstract][Full Text] [Related]
12. The clinical significance of JAK2V617F mutation for Philadelphia-negative chronic myeloproliferative neoplasms in patients with splanchnic vein thrombosis. Yonal I; Pinarbası B; Hindilerden F; Hancer VS; Nalcaci M; Kaymakoglu S; Diz-Kucukkaya R J Thromb Thrombolysis; 2012 Oct; 34(3):388-96. PubMed ID: 22569900 [TBL] [Abstract][Full Text] [Related]
13. Unlocking the Role of Endothelial MPL Receptor and JAK2V617F Mutation: Insights into Cardiovascular Dysfunction in MPNs and CHIP. Zhang H; Kafeiti N; Lee S; Masarik K; Zheng H; Zhan H bioRxiv; 2023 Jul; ():. PubMed ID: 37503259 [TBL] [Abstract][Full Text] [Related]
14. JAK2V617F Megakaryocytes Promote Hematopoietic Stem/Progenitor Cell Expansion in Mice Through Thrombopoietin/MPL Signaling. Zhang Y; Lin CHS; Kaushansky K; Zhan H Stem Cells; 2018 Nov; 36(11):1676-1684. PubMed ID: 30005133 [TBL] [Abstract][Full Text] [Related]
15. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs). Dunbar A; Nazir A; Levine R Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953 [TBL] [Abstract][Full Text] [Related]
16. Cardiac hypertrophy associated with myeloproliferative neoplasms in JAK2V617F transgenic mice. Shi K; Zhao W; Chen Y; Ho WT; Yang P; Zhao ZJ J Hematol Oncol; 2014 Mar; 7():25. PubMed ID: 24646493 [TBL] [Abstract][Full Text] [Related]
17. Platelets and neutrophils cooperate to induce increased neutrophil extracellular trap formation in JAK2V617F myeloproliferative neoplasms. Guy A; Garcia G; Gourdou-Latyszenok V; Wolff-Trombini L; Josserand L; Kimmerlin Q; Favre S; Kilani B; Marty C; Boulaftali Y; Labrouche-Colomer S; Mansier O; James C J Thromb Haemost; 2024 Jan; 22(1):172-187. PubMed ID: 37678548 [TBL] [Abstract][Full Text] [Related]
18. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Smalberg JH; Arends LR; Valla DC; Kiladjian JJ; Janssen HL; Leebeek FW Blood; 2012 Dec; 120(25):4921-8. PubMed ID: 23043069 [TBL] [Abstract][Full Text] [Related]
19. Erythrocyte-derived microvesicles induce arterial spasms in JAK2V617F myeloproliferative neoplasm. Poisson J; Tanguy M; Davy H; Camara F; El Mdawar MB; Kheloufi M; Dagher T; Devue C; Lasselin J; Plessier A; Merchant S; Blanc-Brude O; Souyri M; Mougenot N; Dingli F; Loew D; Hatem SN; James C; Villeval JL; Boulanger CM; Rautou PE J Clin Invest; 2020 May; 130(5):2630-2643. PubMed ID: 32045382 [TBL] [Abstract][Full Text] [Related]